

Clinicopathological significance of *p15* promoter hypermethylation in multiple myeloma: a meta-analysis

Bing Wei
Shuhua Yang
Bo Zhang
Yong Feng

Department of Orthopaedic Surgery,
Union Hospital, Tongji Medical
College, Huazhong University of
Science and Technology, Wuhan,
People's Republic of China

Abstract: Published studies reported that loss of function of the *p15^{INK4B}* gene is caused by hypermethylation; however, whether or not the inactivation is associated with the incidence and clinical significance of multiple myeloma (MM) remains unclear. In this study, we performed a meta-analysis to quantitatively determine the effects of *p15* hypermethylation on the incidence of MM. The related research articles in English and Chinese languages were evaluated. The data were extracted and assessed independently. The pooled data were analyzed and odds ratios were calculated and summarized. Sixteen eligible studies were selected for final analysis. We demonstrated that *p15* hypermethylation is significantly higher in MM than that in normal bone marrow, as well as monoclonal gammopathy of undetermined significance. However, aberrant *p15* hypermethylation was not significantly higher in advanced MM than that in early-stage MM. The results of this study reveal that *p15* hypermethylation is correlated with an increased risk in the progression of monoclonal gammopathy of undetermined significance to MM. *p15* hypermethylation, which induces the loss of function of the *p15* gene, plays a critical role in the early tumorigenesis of MM and serves as a reputable diagnostic marker and potential drug target.

Keywords: *p15^{INK4B}*, methylation, asymptomatic monoclonal gammopathy of undetermined significance, tumor suppressor gene, odds ratio, meta-analysis

Introduction

Multiple myeloma (MM) is a clonal malignancy characterized by the production of monoclonal immunoglobulin and the proliferation of malignant plasma cells in the bone marrow.¹ Clinically, MM starts with immortalization of a post-germinal center B cell and presents as asymptomatic monoclonal gammopathy of undetermined significance (MGUS). MGUS plasma cells share many abnormal characteristics with MM plasma cells. MGUS is considered as the precursor of MM, since it is able to progress to symptomatic MM at a rate of 1% per year.² Over the years, newly approved drugs such as bortezomib, lenalidomide, and thalidomide have shown significant benefits in heavily pretreated MM patients.³⁻⁶ However, the majority of MM patients still relapse; therefore, the identification of biomarker and potential drug target is still necessary to improve the survival rate in the patients who are refractory to chemotherapy. Epigenetic alteration, particularly aberrant DNA methylation, is one of the best-characterized epigenetic modifications contributing to tumor initiation, progression, and prognosis.⁷⁻⁹ CpG islands of tumor suppressor genes are aberrantly methylated (hypermethylation), which result in transcriptional repression and loss of function of genes in many tumors

Correspondence: Yong Feng
Department of Orthopaedic Surgery,
Union Hospital, Tongji Medical College,
Huazhong University of Science and
Technology, 1277 Jiefang Avenue, Wuhan
430022, People's Republic of China
Email yongfengmd@yeah.net

including MM.^{10–12} The *p15*, as a tumor suppression gene, is hypermethylated in many tumors including MM.

p15^{INK4b} (*p15*), one of the INK4 members, is a cyclin-dependent kinase inhibitor.^{13,14} Previously, *p15^{INK4b}*, as well as other INK4 members, *p14^{ARF}*, *p16^{INK4a}*, *p21^{CIP1}*, and *p27^{KIP2}*, have been revealed to be involved in the neoplastic process of carcinomas.^{15,16} Although a number of reports have determined that the inactivation of *p15* gene is mainly induced by hypermethylation in MM, the reported rates of *p15* hypermethylation in MM are remarkably diverse. In addition, whether or not the inactivation of *p15* gene is associated with the incidence and clinical significance of MM has not been thoroughly determined. Hence, we performed a systematic review and meta-analysis to determine the effects of *p15* hypermethylation on the incidence and clinical significance of MM.

Methods

Search strategy and selection criteria

We identified studies from Embase, ISI web, and PubMed from August 1, 1995 to July, 2015 using the following search terms: “multiple myeloma”, “Kahler’s disease”, “plasma cell myeloma”, “methylation”, “*p15*”, “*p15^{INK4B}*”, and “cyclin-dependent kinase inhibitor 2B”. We also manually searched reviews for additional related articles and the reference lists of the retrieved articles. We only took into account the studies published in the English and Chinese languages for full-text reading and final evaluations. After the exclusion of redundant and/or nonrelevant publications from different databases, the remaining articles were analyzed and evaluated in the full-text version for inclusion and exclusion criteria.

To be eligible, a study needed to meet the following criteria: 1) *p15* methylation evaluated in primary MM; 2) *p15* methylation determined by polymerase chain reaction (PCR); 3) research revealed the relationship between *p15* methylation of MM clinicopathological parameters and prognosis; and 4) studies provided sufficient data and information to determine odds ratio (OR). The exclusion criteria included: 1) case reports, conference abstracts, letters, reviews, editorials, and expert opinion; and 2) all publications regarding in vitro/ex vivo studies, cell lines, and human xenografts. In addition to inclusion criteria, “aberrant” *p15* methylation or *p15* hypermethylation is defined by clear PCR product band detected by methylation-specific polymerase chain reaction (MSP).

Data extraction and methodological assessment

Two authors (BW, SY) independently reviewed and extracted data from eligible studies. Two authors (BZ, YF) reviewed

all the articles that fit the inclusion and exclusion criteria. Disagreements were resolved through discussion and consensus. For each study, the following information was recorded: year of publication, the first author name, number of cases, sample source, methylation detection method, clinicopathological parameters, methylation rate, and follow-up results. Heterogeneity of investigations was evaluated to determine whether or not the data of the various studies could be analyzed.

Three investigators (BW, SY, and BZ) read through each publication independently for the methodological evaluation of the studies, and assessed and scored them according to the Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) guidelines and European Lung Cancer Working Party (ELCWP) quality scale.^{17,18} They provided the quality scores and reached a consensus value for each item.

Statistical analysis

The Review Manager 5.2 (Cochrane Collaboration, Oxford, UK) and STATA 12.0 (StataCorp LP, College Station, TX, USA) were selected for analysis. The frequency of *p15* promoter hypermethylation was compared in different tumor characteristics. The pooled frequency of *p15* promoter hypermethylation and 95% confidence intervals (CIs) were estimated. Cochran’s *Q* test¹⁹ and the *I*² statistic were used for evaluating heterogeneity among studies.^{20,21} A fixed-effect model was used to calculate parameters when heterogeneity was not an issue (*I*² values <50%). A random-effects model was used to pool data and attempt to identify potential sources of heterogeneity based on subgroup analyses, if there was substantial heterogeneity (*I*² values ≥50%). *P*-values tailed less than 0.05 were considered statistically significant.

The method reported by Egger et al was used for assessing publication bias.²² Meta-regression, subgroup analysis, and sensitivity analysis were used for exploring reasons of statistical heterogeneity. STATA version 10.0 was used for the analysis of meta-regression and publication bias.

Results

Sixteen studies published from 1997 to 2014 were included in the meta-analysis, as shown in Figure 1. A total of 607 patients from Argentina, Brazil, the People’s Republic of China, Hong Kong, France, Spain, Austria, and USA were enrolled; Table 1 showed their basic characteristics.

The meta-analysis showed that *P15* hypermethylation is significantly higher in MM than that in normal bone marrow samples. The pooled OR from 15 studies, including 571 MM and 193 normal bone marrow, are shown in Figure 2 (OR=19.80, 95% CI=9.21–42.56, *P*<0.00001), which




Figure 1 Flowchart of study selection.

Table 1 Basic characteristics of the included studies in MM

Study	Country	Number of patients	Methods	Primary aim	Methylation site	p15 expression
Li et al ³⁷	People's Republic of China	54	MSP	Determine the methylation status of <i>p15</i> gene in MM	Promoter, CpG islands	–
Stanganelli et al ³⁵	Argentina	44	MSP	Determine the methylation status of <i>p15</i> in the progression of MM	Promoter, CpG islands	–
Braggio et al ²⁸	Brazil	68	MSP	Determine the methylation status of nine tumor suppressor genes including <i>p15</i> in MM	Promoter, CpG islands	–
Martin et al ³⁸	Spain	30	MSP	Determine the methylation status of six tumor suppressor genes including <i>p15</i> in MM	Promoter, CpG islands	–
Jiang et al ³⁹	People's Republic of China	33	MSP	To explore the correlation between <i>p15</i> gene methylation in pathogenesis of MM	Promoter, CpG islands	–
Liang et al ⁴⁰	People's Republic of China	28	MSP, RT-PCR	Determine the methylation status of <i>p15</i> gene in MM	First exon, CpG islands	+
Chim et al ⁴¹	Hong Kong	13	MSP	Determine the methylation status of ten tumor suppressor genes including <i>p15</i> in MM	Promoter, CpG islands	–
Seidl et al ⁴²	Austria	113	MSP	Determine the methylation frequencies of ten genes including <i>p15</i> in patients with monoclonal gammopathies.	Promoter, CpG islands	–
Galm et al ²⁵	USA	56	MSP	Determine the methylation status of eleven tumor suppressor genes including <i>p15</i> in MM	Promoter, CpG islands	–
Chen et al ⁴³	People's Republic of China	22	MSP	Determine the methylation frequencies of <i>p15</i> and <i>p16</i> in MM	Promoter, CpG islands	–
Fu et al ⁴⁴	People's Republic of China	42	MSP	Determine the methylation status of <i>p15</i> in MM and MGUS	Promoter, CpG islands	–
Guo et al ⁴⁵	People's Republic of China	23	MSP	Determine the methylation status of <i>p15</i> in MM	Promoter, CpG islands	–
Guillerm et al ⁴⁶	France	33	MSP	Determine <i>p15</i> and <i>p16</i> methylation in the progression of MM	Promoter, CpG islands	–
Wu et al ⁴⁷	People's Republic of China	12	MSP	To study the effect of <i>p15</i> hypermethylation in MM	Promoter, CpG islands	–
Fan et al ⁴⁸	People's Republic of China	24	MSP	Determine methylation status of <i>p15</i> and <i>p16</i> genes in MM	Promoter, CpG islands	–
Ng et al ²⁹	Hong Kong	12	MSP	To investigate whether <i>p15</i> and <i>p16</i> deactivated by deletions, mutations, and hypermethylation in MM	Promoter, CpG islands	–

Notes: “+” p15 protein was detected. “–” p15 protein was not detected.

Abbreviations: MGUS, monoclonal gammopathy of undetermined significance; MM, multiple myeloma; MSP, methylation-specific polymerase chain reaction; RT-PCR, reverse transcription-polymerase chain reaction.




Figure 2 Fifteen studies, including 571 MM and 193 normal bone marrow cases, investigated *p15* hypermethylation status between MM patients and normal individuals (pooled OR=19.80, 95% CI=9.21–42.56, $P<0.00001$).

Abbreviations: CI, confidence interval; MM, multiple myeloma; OR, odds ratio; df , degrees of freedom; M-H, Mantel-Haenszel.

indicates that *p15* inactivation through hypermethylation plays an important role in the pathogenesis of MM. We further determined that *p15* hypermethylation also occurs in MGUS, which is significantly less than that in MM (OR=2.25, 95% CI=1.20–4.21, $P=0.01$); the pooled frequency rate of the *p15* hypermethylation in MM is 26.7% whereas in MGUS it is 13.9%, as shown in Figure 3A, but higher than that in normal bone marrow (OR=5.40, 95% CI=1.09–26.86, $P=0.04$), as shown in Figure 3B.

We analyzed 179 MM patients pooled in five studies to assess whether or not the aberrant *p15* hypermethylation in MM was associated with advanced stages of MM. As shown in Figure 4, aberrant *p15* hypermethylation is not significantly higher in advanced MM (Stage III) than that in early-stage MM (Stage I and II) (OR=1.17, 95% CI=0.54–2.54, $P=0.69$). Staging of MM is the process of finding out the amount of malignant myeloma cells that have advanced; it relies mainly on levels of albumin and beta-2-microglobulin in the blood, platelet count, kidney function, and patient's age.^{23,24} MM stages which are equivalent to progression are determined by evolving mutations and epigenetic mechanisms. Our results suggest that the inactivation of *p15* gene expression by promoter hypermethylation may not play an important role in MM progression.

Finally, we performed sensitivity analyses, in which one study at a time was removed, to assess the result stability. The pooled ORs were not significantly changed, indicating the stability of our analyses. The funnel plots are largely symmetric (Figure 5), suggesting there were no publication biases in the meta-analysis of *p15* hypermethylation and clinicopathological features.

Discussion

The *p15* gene, along with *p14* and *p16*, is the most prevalent hypermethylated cell cycle regulatory gene in tumorigenesis and progression of MM.^{25–29} We conducted this meta-analysis to determine the correlation between *p15* hypermethylation and MM. Analysis of the pooled data showed that 1) significantly higher *p15* hypermethylation was detected in MM than that in normal bone marrow; 2) *p15* hypermethylation was also detected in MGUS, but significantly less than that in MM; 3) *p15* hypermethylation was also higher in MGUS than that in normal bone marrow; and 4) *p15* hypermethylation was not significantly higher in advanced MM than that in early-stage MM. Epigenetic changes contribute to tumorigenesis and affect initial steps in malignant transformation by altering genome stability and regulating gene expression.³⁰ MM develops as a result




Figure 3 (A) Six of included studies investigated *p15* hypermethylation status between 315 patients with multiple myeloma (MM) and 101 MGUS (pooled OR=2.25, 95% CI=1.20–4.21, $P=0.01$). **(B)** Four of included studies investigated *p15* hypermethylation status between 65 patients with MGUS and 33 normal bone marrow (pooled OR=5.40, 95% CI=1.09–26.86, $P=0.04$).

Abbreviations: CI, confidence interval; MGUS, monoclonal gammopathy of undetermined significance; MM, multiple myeloma; OR, odds ratio; df , degrees of freedom; M-H, Mantel–Haenszel.

of multistep tumorigenic events, in which approximately one-third of all MM cases have a history of preceding MGUS or smoldering myeloma. Recent data also show that MM is consistently preceded by a precursor state, MGUS.^{31–33} MGUS, a premalignant and early stage of myeloma, was

characterized by striking, widespread hypomethylation while gene-specific hypermethylation was found to occur in the advanced stages of myeloma.³⁰ We noticed that Wang et al²⁷ have performed a meta-analysis on *p15* and *p16* genes in MM; however, the role of *p15* hypermethylation in different




Figure 4 The pooled OR from five studies including 179 MM patients. Aberrant *p15* hypermethylation was not significantly higher in advanced MM (Stage III) than that in early-stage MM (Stage I and II) (OR=1.17, 95% CI=0.54–2.54, $P=0.69$).

Abbreviations: CI, confidence interval; MM, multiple myeloma; OR, odds ratio; df , degrees of freedom; M-H, Mantel–Haenszel.




Figure 5 Funnel plot of publication bias in the meta-analysis of *p15* hypermethylation and clinicopathological features.

Notes: (A) The funnel plot from 15 studies comparing MM and normal bone marrow. (B) The funnel plot from six studies comparing MM and MGUS. (C) The funnel plot from four studies comparing MGUS and normal bone marrow. (D) The funnel plot from five studies comparing different stage MM patients (Stage III vs Stage I and II).

Abbreviations: CI, confidence interval; MGUS, monoclonal gammopathy of undetermined significance; MM, multiple myeloma; OR, odds ratio; SE, standard error.

stages of MM was not elucidated. The results from the current study demonstrates that the hypermethylation rate of *p15* gene promoter in MGUS was higher than that in normal bone marrow, indicating that *p15* promoter hypermethylation was an early event in myelomagenesis. We did not find that *p15* hypermethylation in MM was associated with advanced stage. These results also indicate that *p15* hypermethylation could potentially be an early event. The results that significantly higher *p15* hypermethylation was detected in MM than that in normal bone marrow and MGUS indicate that *p15* hypermethylation is common in MM. Since changes in *p15* hypermethylation are reversible, drug treatment through demethylation may be useful to delay carcinogenesis and progression. This approach may bring new direction and hope for MM treatment through gene-targeted therapy.

Progression from MGUS to MM appears to mirror the accumulation of genetic abnormalities, suggesting a stepwise progression of genetic and epigenetic changes.³⁴ Hypermethylation of several tumor suppressors, such as *p15*, *ARF*,

SOCs-1, *p27 KIP1*, *RASSF1A*, non-receptor type 6 (SHP1), death-associated protein kinase, and *TP73* genes was reported in MGUS.^{35,36} Our meta-analysis showed that *p15* gene hypermethylation in MGUS is higher than that in normal cohort. Our results also showed that *p15* hypermethylation in MGUS was significantly less than that in MM. Therefore, hypermethylation of the *p15* gene could potentially be involved in the progression of MGUS to MM. In addition, combining *p15* with other tumor suppressor genes to develop several gene markers will be a valuable strategy for risk stratification to predict initial carcinogenesis and neoplastic progression of MM.

Limitations

This study has several potential limitations. First, the search strategy was restricted to articles published in English and Chinese. Articles with potentially high-quality data that were published in other languages were not included because of anticipated difficulties in obtaining accurate medical

translation. Second, the possibility of information and selection biases as well as unidentified confounders could not be completely excluded because all of the included studies were observational. Hence, caution should be taken when our findings are interpreted among the general populations. In addition, for MSP detection, it is usually to detect CpG island regions in the gene promoter or the first exon. The different location of detection sites may affect the methylation rate.

Conclusion

We performed a meta-analysis of 16 eligible studies. Our results demonstrated that *p15* hypermethylation is significantly higher in MM than that in normal bone marrow, as well as in MGUS. However, aberrant *p15* hypermethylation was not significantly higher in advanced MM than that in early-stage MM. The results of this meta-analysis suggest that *p15* hypermethylation is associated with an increased risk in the progression of MGUS to MM. *p15* hypermethylation, which induces the inactivation of *p15* gene, plays an important role in the early tumorigenesis of MM and serves as a reputable prognostic marker and potential drug target.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Rollig C, Illmer T. The efficacy of arsenic trioxide for the treatment of relapsed and refractory multiple myeloma: a systematic review. *Cancer Treat Rev*. 2009;35(5):425–430.
2. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. *N Engl J Med*. 2002;346(8):564–569.
3. Shank BR, Brown VT, Schwartz RN. Multiple myeloma maintenance therapy: a review of the pharmacologic treatment. *J Oncol Pharm Pract*. 2015;21(1):36–51.
4. Latif T, Chauhan N, Khan R, Moran A, Usmani SZ. Thalidomide and its analogues in the treatment of multiple myeloma. *Exp Hematol Oncol*. 2012;1(1):27.
5. Yang B, Yu RL, Chi XH, Lu XC. Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials. *PLoS One*. 2013;8(5):e64354.
6. Romano A, Conticello C, Di Raimondo F. Bortezomib for the treatment of previously untreated multiple myeloma. *Immunotherapy*. 2013; 5(4):327–352.
7. Delpu Y, Cordelier P, Cho WC, Torrisani J. DNA methylation and cancer diagnosis. *Int J Mol Sci*. 2013;14(7):15029–15058.
8. Ma X, Wang YW, Zhang MQ, Gazdar AF. DNA methylation data analysis and its application to cancer research. *Epigenomics*. 2013; 5(3):301–316.
9. Fukushima S, Horii A. DNA methylation in cancer: a gene silencing mechanism and the clinical potential of its biomarkers. *Tohoku J Exp Med*. 2013;229(3):173–185.
10. Chim CS, Kwong YL, Liang R. Gene hypermethylation in multiple myeloma: lessons from a cancer pathway approach. *Clin Lymphoma Myeloma*. 2008;8(6):331–339.
11. Ehrlich M, Lacey M. DNA methylation and differentiation: silencing, upregulation and modulation of gene expression. *Epigenomics*. 2013; 5(5):553–568.
12. Akhavan-Niaki H, Samadani AA. DNA methylation and cancer development: molecular mechanism. *Cell Biochem Biophys*. 2013;67(2): 501–513.
13. Reynisdottir I, Polyak K, Iavarone A, Massague J. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. *Genes Dev*. 1995;9(15):1831–1845.
14. Herman JG, Jen J, Merlo A, Baylin SB. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. *Cancer Res*. 1996;56(4):722–727.
15. Wolff L, Bies J. p15Ink4b Functions in determining hematopoietic cell fates: implications for its role as a tumor suppressor. *Blood Cells Mol Dis*. 2013;50(4):227–231.
16. Heyman M, Einhorn S. Inactivation of the p15INK4B and p16INK4 genes in hematologic malignancies. *Leuk Lymphoma*. 1996;23(3–4): 235–245.
17. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). *J Natl Cancer Inst*. 2005;97(16):1180–1184.
18. Steels E, Paesmans M, Berghmans T, et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. *Eur Respir J*. 2001;18(4):705–719.
19. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. 1986;7(3):177–188.
20. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ*. 2003;327(7414):557–560.
21. DerSimonian R. Meta-analysis in the design and monitoring of clinical trials. *Stat Med*. 1996;15(12):1237–1248; discussion 49–52.
22. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ*. 1997;315(7109):629–634.
23. Ribatti D, Moschetta M, Vacca A. Microenvironment and multiple myeloma spread. *Thromb Res*. 2014;133(Suppl 2):S102–S106.
24. Ria R, Reale A, Vacca A. Novel agents and new therapeutic approaches for treatment of multiple myeloma. *World J Methodol*. 2014;4(2): 73–90.
25. Galm O, Wilop S, Reichelt J, et al. DNA methylation changes in multiple myeloma. *Leukemia*. 2004;18(10):1687–1692.
26. Guillemin G, Depil S, Wolowicz D, Quesnel B. Different prognostic values of p15(INK4b) and p16(INK4a) gene methylations in multiple myeloma. *Haematologica*. 2003;88(4):476–478.
27. Wang X, Zhu YB, Cui HP, Yu TT. Aberrant promoter methylation of p15 (INK4b) and p16 (INK4a) genes may contribute to the pathogenesis of multiple myeloma: a meta-analysis. *Tumour Biol*. 2014;35(9): 9035–9043.
28. Braggio E, Maiolino A, Gouveia ME, et al. Methylation status of nine tumor suppressor genes in multiple myeloma. *Int J Hematol*. 2010; 91(1):87–96.
29. Ng MH, Chung YF, Lo KW, Wickham NW, Lee JC, Huang DP. Frequent hypermethylation of p16 and p15 genes in multiple myeloma. *Blood*. 1997;89(7):2500–2506.
30. Heuck CJ, Mehta J, Bhagat T, et al. Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis. *J Immunol*. 2013;190(6):2966–2975.
31. Landgren O. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies. *Hematology Am Soc Hematol Educ Program*. 2013; 2013:478–487.
32. Agarwal A, Ghobrial IM. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease. *Clin Cancer Res*. 2013;19(5):985–994.
33. Greenberg AJ, Rajkumar SV, Vachon CM. Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics. *Blood*. 2012; 119(23):5359–5366.

34. Iida S, Ueda R. Multistep tumorigenesis of multiple myeloma: its molecular delineation. *Int J Hematol*. 2003;77(3):207–212.
35. Stanganelli C, Arbelbide J, Fantl DB, Corrado C, Slavutsky I. DNA methylation analysis of tumor suppressor genes in monoclonal gammopathy of undetermined significance. *Ann Hematol*. 2010; 89(2):191–199.
36. Chim CS, Liang R, Leung MH, Kwong YL. Aberrant gene methylation implicated in the progression of monoclonal gammopathy of undetermined significance to multiple myeloma. *J Clin Pathol*. 2007; 60(1):104–106.
37. Li C, Yang L, Liu L, et al. Study on methylation and mRNA expression of p15 gene in multiple myeloma. *Med Pharm Yunnan*. 2014;3:1–3. Chinese.
38. Martin P, Garcia-Cosio M, Santon A, Bellas C. Aberrant gene promoter methylation in plasma cell dyscrasias. *Exp Mol Pathol*. 2008;84(3): 256–261.
39. Jiang J, Lin S, Chen G, Yan J. The significance of p15 gene methylation in multiple myeloma. *J Clin Hematol*. 2007;20(2):104–105. Chinese.
40. Liang X, Jiang Y, Xu W, Liu J. Study on hypermethylation and mRNA expression of p16 and p15 gene in multiple myeloma. *Clin Focus*. 2006;21(1):10–13.
41. Chim CS, Kwong YL, Fung TK, Liang R. Methylation profiling in multiple myeloma. *Leuk Res*. 2004;28(4):379–385.
42. Seidl S, Ackermann J, Kaufmann H, et al. DNA-methylation analysis identifies the E-cadherin gene as a potential marker of disease progression in patients with monoclonal gammopathies. *Cancer*. 2004;100(12): 2598–2606.
43. Chen W, Wu Y, Zhu J, Liu J, Tan S, Xia C. Methylation of p16 and p15 genes in multiple myeloma. *Chin Med Sci J*. 2002;17(2):101–105.
44. Fu W, Gao W, Hou J, Wang D, Ding S, Chen Q. Hypermethylation of CpG island of p15 and p16 genes in multiple myeloma. *Cancer Prev Cure Res*. 2002;2(29):1–2.
45. Guo X, Fan H, Tan G, et al. Study of p15 gene methylation status in multiple myeloma. *Chin J Pathophysiol*. 2001;17(7):679–682.
46. Guillermin G, Gyan E, Wolowiec D, et al. p16(INK4a) and p15(INK4b) gene methylations in plasma cells from monoclonal gammopathy of undetermined significance. *Blood*. 2001;98(1):244–246.
47. Wu Q, Guo X, Fan H, et al. [P15(INK4B) gene methylation in malignant hematopoietic diseases]. *Zhonghua Xue Ye Xue Za Zhi*. 2000;21(12):644–646. Chinese.
48. Fan H, Guo X, Wu Q, et al. [Detection of high methylation of p15(INK4B) and p16(INK4A) genes in multiple myeloma]. *Zhongguo Shi Yan Xue Ye Xue Za Zhi*. 2000;8(4):271–274. Chinese.

OncoTargets and Therapy

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on

Submit your manuscript here: <http://www.dovepress.com/oncotargets-and-therapy-journal>

patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Dovepress